Literature DB >> 12543691

Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice.

Pieter Leyssen1, Christian Drosten, Marcus Paning, Nathalie Charlier, Jan Paeshuyse, Erik De Clercq, Johan Neyts.   

Abstract

We evaluated the prophylactic and therapeutic efficacy of interferon alpha-2b, pegylated interferon alpha-2b, poly(I. C), and Ampligen against Modoc virus encephalitis in an animal model for flavivirus infections. All compounds significantly delayed virus-induced morbidity (paralysis) and mortality (due to progressive encephalitis). Viral load (as measured on day 7 postinfection) was significantly reduced by 80 to 100% in the serum, brain, and spleen in mice that had been treated with either interferon alpha-2b, pegylated interferon alpha-2b, poly(I. C), or Ampligen. We also studied whether a combination of interferon alpha-2b and ribavirin (presently the standard therapy for the treatment of infections with hepatitis C virus) would be more effective than treatment with interferon alone. However, ribavirin did not enhance the inhibitory effect of interferon therapy in this animal model for flavivirus infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543691      PMCID: PMC151739          DOI: 10.1128/AAC.47.2.777-782.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Mechanisms of action of ribavirin in antiviral therapies.

Authors:  R C Tam; J Y Lau; Z Hong
Journal:  Antivir Chem Chemother       Date:  2001-09

2.  Intranasal infection of monkeys with Japanese encephalitis virus: clinical response and treatment with a nuclease-resistant derivative of poly (I).poly (C).

Authors:  D G Harrington; D E Hilmas; M R Elwell; R E Whitmire; E L Stephen
Journal:  Am J Trop Med Hyg       Date:  1977-11       Impact factor: 2.345

Review 3.  Ribavirin's antiviral mechanism of action: lethal mutagenesis?

Authors:  Shane Crotty; Craig Cameron; Raul Andino
Journal:  J Mol Med (Berl)       Date:  2001-12-04       Impact factor: 4.599

4.  Enhanced resistance of mice to virulent Japanese B encephalitis virus following inactivated vaccine and poly I:C.

Authors:  B Singh; B Postic
Journal:  J Infect Dis       Date:  1970-10       Impact factor: 5.226

5.  The influence of Poly I:C on the course of infection in mice inoculated with West Nile virus.

Authors:  S Haahr
Journal:  Arch Gesamte Virusforsch       Date:  1971

Review 6.  The molecular biology of tick-borne encephalitis virus. Review article.

Authors:  F X Heinz; C W Mandl
Journal:  APMIS       Date:  1993-10       Impact factor: 3.205

7.  Comparative therapeutic efficacy of recombinant interferons-alpha, -beta, and -gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections.

Authors:  A J Pinto; P S Morahan; M Brinton; D Stewart; E Gavin
Journal:  J Interferon Res       Date:  1990-06

Review 8.  Yellow fever: a medically neglected disease. Report on a seminar.

Authors:  T P Monath
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 9.  Australian X disease, Murray Valley encephalitis and the French connection.

Authors:  J S Mackenzie; A K Broom
Journal:  Vet Microbiol       Date:  1995-09       Impact factor: 3.293

10.  The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand.

Authors:  C Harinasuta; S Nimmanitya; U Titsyakorn
Journal:  Southeast Asian J Trop Med Public Health       Date:  1985-06       Impact factor: 0.267

View more
  20 in total

1.  Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model.

Authors:  Justin G Julander; Venkatraman Siddharthan; Lawrence M Blatt; Kristiina Schafer; Robert W Sidwell; John D Morrey
Journal:  Virology       Date:  2006-11-21       Impact factor: 3.616

2.  Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice.

Authors:  Aaron L Olsen; John D Morrey; Donald F Smee; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-20       Impact factor: 5.970

3.  Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43.

Authors:  Magdalena Sarasin-Filipowicz; Xueya Wang; Ming Yan; Francois H T Duong; Valeria Poli; Douglas J Hilton; Dong-Er Zhang; Markus H Heim
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

4.  Prophylactic treatment with recombinant Eimeria protein, alone or in combination with an agonist cocktail, protects mice from Banzi virus infection.

Authors:  Justin G Julander; John W Judge; Aaron L Olsen; Barnett Rosenberg; Kristiina Schafer; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-04       Impact factor: 5.970

5.  Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.

Authors:  M C Georges-Courbot; H Contamin; C Faure; P Loth; S Baize; P Leyssen; J Neyts; V Deubel
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Tick-borne encephalitis virus delays interferon induction and hides its double-stranded RNA in intracellular membrane vesicles.

Authors:  Anna K Overby; Vsevolod L Popov; Matthias Niedrig; Friedemann Weber
Journal:  J Virol       Date:  2010-06-16       Impact factor: 5.103

7.  Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production.

Authors:  Nigel Bourne; Frank Scholle; Maria Carlan Silva; Shannan L Rossi; Nathan Dewsbury; Barbara Judy; Juliana B De Aguiar; Megan A Leon; D Mark Estes; Rafik Fayzulin; Peter W Mason
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

8.  Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus.

Authors:  Marcel Asper; Thomas Sternsdorf; Meike Hass; Christian Drosten; Antje Rhode; Herbert Schmitz; Stephan Günther
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection.

Authors:  Justin G Julander; Ramona Skirpstunas; Venkatraman Siddharthan; Kristiina Shafer; Justin D Hoopes; Donald F Smee; John D Morrey
Journal:  Antiviral Res       Date:  2008-02-13       Impact factor: 5.970

10.  A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.

Authors:  Craig W Day; Ralph Baric; Sui Xiong Cai; Matt Frieman; Yohichi Kumaki; John D Morrey; Donald F Smee; Dale L Barnard
Journal:  Virology       Date:  2009-10-22       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.